Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC

This study is a prospective,open-label,single-arm clinical trial to evaluate the efficacy and safety of s Surufatinib combined with envolizumab as second-line treatment of recurrent/metastatic head and neck squamous cell carcinoma . envolizumab: 300 mg subcutaneously every 3 weeks (Q3W); Surufatinib : 200 mg orally within 1 hour after breakfast, once daily continuously every 3 weeks as a treatment cycle until intolerable toxicity or disease progression. If any ≥ Grade 2 treatment-related adverse event occurs during treatment, the dose may be adjusted to 100 mg according to the investigator 's

Trial Details

NCT ID
NCT06876844
Phase
PHASE2
Sponsor
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • combination of Surufatinib and Envolizumab
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Subjects must meet all of the following criteria for enrollment:
  • Have fully understood the study and voluntarily signed the informed consent form;
  • Age: 18-75 years (calculated from the day of informed consent, including the boundary value), both male and female;
  • Pathologically or histologically confirmed recurrent/metastatic head and neck squamous cell carcinoma (excluding nasopharyngeal carcinoma)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →